| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 04/21/2005 | WO2005034837A2 7H-IMIDAZO [1,2-α] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS |
| 04/21/2005 | WO2005020928A3 Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| 04/21/2005 | WO2005020882A3 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 04/21/2005 | WO2005016229A3 Use of lipophilic diesters of chelating agent for the treatment of amyloidosis and atherosclerosis |
| 04/21/2005 | WO2005013907A3 Pyrrolo[1,2-b]pyridazine derivatives |
| 04/21/2005 | WO2005007083A3 Chemical compounds |
| 04/21/2005 | WO2005004803A3 Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
| 04/21/2005 | WO2005002528A3 Method for treating diabetes |
| 04/21/2005 | WO2005000239A3 Lyase treatment for p. carinii |
| 04/21/2005 | WO2005000208A3 Combination therapy for the treatment of neoplasms |
| 04/21/2005 | WO2004110361A3 Anticancer compositions comprising methenamine |
| 04/21/2005 | WO2004105678A3 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions |
| 04/21/2005 | WO2004103268A3 Intracellular production of specific rna molecules by splicing |
| 04/21/2005 | WO2004098490A3 Mesoderm and definitive endoderm cell populations |
| 04/21/2005 | WO2004096268A3 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
| 04/21/2005 | WO2004093809A3 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| 04/21/2005 | WO2004091530B1 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
| 04/21/2005 | WO2004089291A3 Tumor-targeting drug-loaded particles |
| 04/21/2005 | WO2004089286A3 Novel compounds and compositions as protein kinase inhibitors |
| 04/21/2005 | WO2004082616A3 Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity |
| 04/21/2005 | WO2004073657A3 Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases |
| 04/21/2005 | WO2004073649A3 Clk-peptide and slk-peptide |
| 04/21/2005 | WO2004071462A3 Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction |
| 04/21/2005 | WO2004071386A3 Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use |
| 04/21/2005 | WO2004069291A3 Instrument for assisting in the remote placement of tied surgical knots and trimming of suture away from the knot and method of use |
| 04/21/2005 | WO2004064739A3 Substrate detection assay |
| 04/21/2005 | WO2004060316A3 Irs modulators |
| 04/21/2005 | WO2004041194A3 Inhibition of hiv-1 replication |
| 04/21/2005 | WO2004041156A3 Method for determining sensitivity to a bacteriophage |
| 04/21/2005 | WO2004021978A3 Antisense modulation of endothelial specific molecule 1 expression |
| 04/21/2005 | US20050085672 Color stabilization of hydroquinone hydroxyethyl ether products |
| 04/21/2005 | US20050085630 Photocleavable isotope-coded affinity tags |
| 04/21/2005 | US20050085540 Compounds and methods for delivery of prostacyclin analogs |
| 04/21/2005 | US20050085511 Cyclic diamines and derivatives as factor Xa inhibitors |
| 04/21/2005 | US20050085479 Synergistic mixture |
| 04/21/2005 | US20050085478 Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
| 04/21/2005 | US20050085477 Antitumor agents; synergistic mixture |
| 04/21/2005 | US20050085472 Pyrazolo pyrimidine derivatives and methods of use thereof |
| 04/21/2005 | US20050085460 useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease |
| 04/21/2005 | US20050085453 Methods for the treatment of endometriosis |
| 04/21/2005 | US20050085418 Ligands for TGF-beta binding proteins and uses thereof |
| 04/21/2005 | US20050084913 Tumor antigen for use as tool in diagnosis, prevention and treatment of cell proliferative disorders; immunotherapy |
| 04/21/2005 | US20050084873 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 04/21/2005 | US20050084551 Morinda citrifolia-based oral care compositions and methods |
| 04/21/2005 | US20050084538 Ultrasonic concentration of drug delivery capsules |
| 04/21/2005 | US20050084534 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| 04/21/2005 | US20050084516 Process for making gel films |
| 04/21/2005 | CA2544733A1 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| 04/21/2005 | CA2544611A1 Method of treating airway diseases with beta-adrenergic inverse agonists |
| 04/21/2005 | CA2542096A1 Thiophene and benzothiophene hydroxamic acid derivatives |
| 04/21/2005 | CA2542077A1 Pyrovalerone analogs and therapeutic uses thereof |
| 04/21/2005 | CA2541809A1 Thioether-substituted benzamides as inhibitors of factor xa |
| 04/21/2005 | CA2541548A1 Treatment of diseases involving erbb2 kinase overexpression |
| 04/21/2005 | CA2541380A1 Use of cell lines to produce active therapeutic proteins |
| 04/21/2005 | CA2541369A1 Photodynamic inactivation of bacterial spores |
| 04/21/2005 | CA2540301A1 A dried biotherapeutic composition, uses, and device and methods for administration thereof |
| 04/21/2005 | CA2539868A1 A method of healing skin wounds in mammals and a composition therefor |
| 04/21/2005 | CA2539346A1 Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| 04/21/2005 | CA2537315A1 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 04/21/2005 | CA2535982A1 Uses of interferons with altered spatial structure |
| 04/21/2005 | CA2535930A1 Inhibitors of cathepsin s |
| 04/21/2005 | CA2533886A1 Methods of reducing risk of infection from pathogens |
| 04/20/2005 | EP1523983A1 Pharmaceutical composition comprising fenofibrate and process for its preparation |
| 04/20/2005 | EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 04/20/2005 | EP1523975A2 Pressurised metered dose inhalers (MDI) |
| 04/20/2005 | EP1523582A2 Rapid, efiicient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 04/20/2005 | EP1226110B1 Bicyclic amino acids as pharmaceutical agents |
| 04/20/2005 | EP1178810B1 Use of bisphosphonic acids for treating angiogenesis |
| 04/20/2005 | EP1082093B8 Anti-germ attachment - composition |
| 04/20/2005 | CN1608139A Digital assay |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |
| 04/20/2005 | CN1608062A Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 04/20/2005 | CN1607948A Composition comprising paracetamol and a bitterness masking component |
| 04/20/2005 | CN1197617C Fish serine proteinases and their pharmaceutical and cosmetic use |
| 04/20/2005 | CN1197569C New treatments for neuropathy |
| 04/19/2005 | US6881755 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 04/19/2005 | US6881743 Pyridine matrix metalloproteinase inhibitors |
| 04/14/2005 | WO2005033278A2 In vivo efficacy of ny-eso-1 plus iscom |
| 04/14/2005 | WO2005032496A2 Hydrolases, nucleic acids encoding them and mehods for making and using them |
| 04/14/2005 | WO2005032495A2 Gene expression profiles and methods of use |
| 04/14/2005 | WO2005032494A2 Lpa receptor agonists and antagonists and methods of use |
| 04/14/2005 | WO2005032492A2 Site and rate selective prodrug formulations of d609 with antioxidant and anticancer activity |
| 04/14/2005 | WO2005032491A2 Methods and compositions for mycoplasma pneumoniae exotoxins |
| 04/14/2005 | WO2005032490A2 Cyclic diamines and derivatives as factor xa inhibitors |
| 04/14/2005 | WO2005032489A2 Coated metal pyrithione particles for treatment of microorganisms |
| 04/14/2005 | WO2005032488A2 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
| 04/14/2005 | WO2005032487A2 Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus |
| 04/14/2005 | WO2005032486A2 A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY |
| 04/14/2005 | WO2005032485A2 Compounds and methods for the treatment of attention-deficit hyperactivity disorder |
| 04/14/2005 | WO2005032484A2 Alkoxy substituted imidazoquinolines |
| 04/14/2005 | WO2005032483A2 Polysaccharides for pulmonary delivery of active agents |
| 04/14/2005 | WO2005032482A2 Treatment of demyelinating autoimmune disease with modified ordered peptides |
| 04/14/2005 | WO2005032481A2 Quinazoline derivatives as medicaments |
| 04/14/2005 | WO2005032480A2 Methods, compositions,, apparatuses containing tetrameric oxygen |
| 04/14/2005 | WO2005032479A2 Compositions and methods for selective inhibition of nicotine acetylcholine receptors |
| 04/14/2005 | WO2005032478A2 Treatment for diabetic microvascular and macrovascular complications |
| 04/14/2005 | WO2005032476A2 Methods and compositions for cpg15-2 |
| 04/14/2005 | WO2005032475A2 In vivo efficacy of ny-eso-1 plus adjuvant |
| 04/14/2005 | WO2005032474A2 Pharmaceutical compositions for prevention of overdose or abuse |
| 04/14/2005 | WO2005032473A2 Chemical treatment for removing cellular and nuclear material from naturally occurring extracellular matrix-based biomaterials |